ECTRIMS – www.brainwork.md

18th September 2020

Ageing in multiple sclerosis – what do we know?

https://www.brainwork.md/content/uploads/2020/09/Brainwork-Ageing-in-multiple-sclerosis-–-what-do-we-know.png 2846 1601 Anna Stelling, PhD Anna Stelling, PhD https://secure.gravatar.com/avatar/03d32c6dd44674dd6ad1a82129cbc197?s=96&d=mm&r=g 18th September 2020 23rd September 2020

“Ageing comes with many issues in multiple sclerosis (MS): progression, comorbidities, cognition problems and response to treatment”, Pierre Duquette (Department of Neuroscience, University of Montreal, Canada), the chair of the…

Anna Stelling, PhD
0
0

18th September 2020

How to promote remyelination in MS

https://www.brainwork.md/content/uploads/2020/09/Brainwork-How-to-promote-remyelination-in-MS.png 2846 1601 Anne Carter, MA (Cantab) Anne Carter, MA (Cantab) https://secure.gravatar.com/avatar/8a0679fc29066255ffcb2a69eacf9ee3?s=96&d=mm&r=g 18th September 2020 18th September 2020

Strategies to promote remyelination was a hot topic at this year’s virtual ACTRIMS/ECTRIMS joint meeting, with three expert presenters each addressing a different aspect of the subject, including the role…

Anne Carter, MA (Cantab)
0
0

17th September 2020

Is disease-modifying treatment in primary progressive multiple sclerosis effective after all?

https://www.brainwork.md/content/uploads/2020/09/Brainwork-ECTRIMS-Is-disease-modifying-treatment-primary-progressive-multiplesclerosis-effective-after-all-scaled.jpg 1703 2560 Anna Stelling, PhD Anna Stelling, PhD https://secure.gravatar.com/avatar/03d32c6dd44674dd6ad1a82129cbc197?s=96&d=mm&r=g 17th September 2020 18th September 2020

Until now, several randomised controlled trials and real-world studies could not show the clinical benefit of disease‑modifying treatments (DMTs) in primary progressive multiple sclerosis (PPMS).1-4 However, some recently published results…

Anna Stelling, PhD
0
0

17th September 2020

Neurofilament light chain levels as a biomarker in multiple sclerosis

https://www.brainwork.md/content/uploads/2020/09/Brainwork-ECTRIMS-Neurofilament-light-chain-levels-as-a-biomarker-in-multiple-sclerosis-scaled.jpg 1703 2560 Anna Stelling, PhD Anna Stelling, PhD https://secure.gravatar.com/avatar/03d32c6dd44674dd6ad1a82129cbc197?s=96&d=mm&r=g 17th September 2020 18th September 2020

It has been previously shown that the neuronal cytoskeletal protein neurofilament light chain (NfL) is released into the blood and cerebrospinal fluid (CSF) upon neuroaxonal injury.1 Hence it was not…

Anna Stelling, PhD
0
0

17th September 2020

Do hormonal changes influence MS in women?

https://www.brainwork.md/content/uploads/2020/09/Brainwork-Do-hormonal-changes-influence-MS-in-women.jpg 2400 1600 Anne Carter, MA (Cantab) Anne Carter, MA (Cantab) https://secure.gravatar.com/avatar/8a0679fc29066255ffcb2a69eacf9ee3?s=96&d=mm&r=g 17th September 2020 23rd September 2020

There is a paradox in multiple sclerosis (MS): females appear to be more susceptible to the disease than males, but also have a better long-term prognosis. Could this be due…

Anne Carter, MA (Cantab)
0
0

25th September 2019

Why B-cell therapies, or why not?

https://www.brainwork.md/content/uploads/2019/09/Brainwork-bcelltherapy.jpg 3848 2300 Peter Stevenson, PhD Peter Stevenson, PhD https://secure.gravatar.com/avatar/c5331bc85b1dc3f9749cac7354ddaaad?s=96&d=mm&r=g 25th September 2019 4th October 2019

The rational for B-cell therapy in multiple sclerosis (MS) was presented during ECTRIMS 2019, with David Baker (Blizard Institute, Queen Mary University of London, UK) posing the question of why…

Peter Stevenson, PhD
0
0

24th September 2019

Are stem cells in MS ready for prime time?

https://www.brainwork.md/content/uploads/2019/09/Brainwork-stem-cells.jpg 2300 1535 Peter Stevenson, PhD Peter Stevenson, PhD https://secure.gravatar.com/avatar/c5331bc85b1dc3f9749cac7354ddaaad?s=96&d=mm&r=g 24th September 2019 26th September 2019

Hot topics continued at ECTRIMS 2019 in Stockholm with Joachim Burman (Department of Neurology, Uppsala University Hospital, Sweden), who stepped up to the podium to discuss autologous haematopoietic stem cell transplantation (aHSCT)…

Peter Stevenson, PhD
1
0

24th September 2019

Enough evidence for vitamin D in MS?

https://www.brainwork.md/content/uploads/2019/09/Brainwork-vitamin-D.jpg 3450 2300 Peter Stevenson, PhD Peter Stevenson, PhD https://secure.gravatar.com/avatar/c5331bc85b1dc3f9749cac7354ddaaad?s=96&d=mm&r=g 24th September 2019 26th September 2019

The role of vitamin D in the treatment of multiple sclerosis (MS) took centre stage during the first day of ECTRIMS 2019 in Stockholm, Sweden. In a ‘Hot Topic’ session,…

Peter Stevenson, PhD
0
0

19th October 2018

Cognitive impairment in MS

https://www.brainwork.md/content/uploads/2018/10/Brainwork-MSCognitive_2048-1.jpg 2048 1153 Mea Holm, PhD Mea Holm, PhD https://secure.gravatar.com/avatar/7a927c1dcef51229f6403ce27328c69e?s=96&d=mm&r=g 19th October 2018 1st February 2019

Up to 70% of MS patients suffer from cognitive decline, which often has a profound impact on an individual’s quality of life. It is little surprise that MS researchers are…

Mea Holm, PhD
0
0

16th October 2018

Serum neurofilament light: A biomarker for disease activity in MS

https://www.brainwork.md/content/uploads/2018/10/MPR425-Brainwork-illustration-soluble-biomarkers-V00-03-20181012.jpg 1920 1080 Mea Holm, PhD Mea Holm, PhD https://secure.gravatar.com/avatar/7a927c1dcef51229f6403ce27328c69e?s=96&d=mm&r=g 16th October 2018 19th October 2018

How close are we to establishing a reliable liquid biomarker for detecting disease onset, progression and treatment response in multiple sclerosis? According to Dr Peter Calabresi (Johns Hopkins, USA) at…

Mea Holm, PhD
1
0